We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,024.00
Bid: 12,024.00
Ask: 12,028.00
Change: 36.00 (0.30%)
Spread: 4.00 (0.033%)
Open: 12,254.00
High: 12,256.00
Low: 12,018.00
Prev. Close: 11,988.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Pfizer Inc

21 May 2014 15:44

RNS Number : 7346H
FIL Limited
21 May 2014
 



 

FORM 8.3

 

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the person whose positions/dealings are being disclosed

FMR LLC and/or one or more of its direct or indirect subsidiaries

And

 FIL Limited and/or one or more of its direct and indirect subsidiaries

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Pfizer Inc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree

(e) Date position held/dealing undertaken

20-May-14

(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?

YES

If YES, specify which:

AstraZeneca Plc

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary Shares

Interests

Short positions

Number

(%)

Number

(%)

(1) Relevant securities owned and/or controlled:

44,925,827

0.70%

2) Derivatives (other than options):

(3) Options and agreements to purchase/sell

2,500

0.00%

TOTAL

 

44,925,827

0.70%

2,500

0.00%

 

Please note the above positions include a transition out of our accounts of 81 shares.

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary shares

Buy

62

29.3500 USD/ Share

Ordinary shares

Buy

58

29.3700 USD/ Share

Ordinary shares

Buy

5,500

29.4449 USD/ Share

Ordinary shares

Buy

1,604

29.4600 USD/ Share

Ordinary shares

Buy

300

29.5100 USD/ Share

Ordinary shares

Sale

6

29.2500 USD/ Share

Ordinary shares

Sale

420

29.3048 USD/ Share

Ordinary shares

Sale

53

29.3100 USD/ Share

Ordinary shares

Sale

370

29.3400 USD/ Share

Ordinary shares

Sale

279

29.3600 USD/ Share

Ordinary shares

Sale

55,400

29.4246 USD/ Share

Ordinary shares

Sale

1,239

29.4550 USD/ Share

Ordinary shares

Sale

6,326

29.4600 USD/ Share

Ordinary shares

Sale

67

29.5000 USD/ Share

Ordinary shares

Sale

121

29.5050 USD/ Share

Ordinary shares

Sale

2,900

29.5100 USD/ Share

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

Yes

 

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the "Code")

 

 

1. KEY INFORMATION

 

Identity of person whose open positions are being disclosed:

PFIZER INC

Name of offeror/offeree in relation to whose relevant securities the disclosure relates:

ASTRAZENECA PLC (UK)

 

2. OPTIONS AND DERIVATIVES

 

Class of relevant security

Product description e.g. call option

Written or purchased

Number of securities to which option or derivative relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

CS

Call Option

Written

1,500

USD 34.00

American

21-06-2014

CS

Call Option

Written

1,000

USD 33.00

American

19-07-2014

 

 

 

Date of disclosure

21-May-14

Contact name

Nevelina Rousseva

Telephone number

01737 837216

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RETQKDDQQBKDNPB
Date   Source Headline
23rd Sep 20217:00 amRNSNew Sustainability Committee of the Board
21st Sep 20217:00 amRNSAstraZeneca $360m Irish manufacturing investment
20th Sep 20217:00 amRNSEnhertu reduced risk of disease progression by 72%
9th Sep 20214:00 pmRNSImfinzi improves survival in NSCLC in POSEIDON
9th Sep 20217:00 amRNSPT027 PhIII asthma trials met primary endpoints
3rd Sep 20217:00 amRNSUltomiris approved in EU for children with PNH
1st Sep 20213:00 pmRNSTotal Voting Rights
26th Aug 20217:05 amRNSForxiga approved in Japan for CKD
26th Aug 20217:00 amRNSALXN1840 Wilson Phase III met primary endpoint
20th Aug 20217:05 amRNSUpdate on Ultomiris Phase III ALS trial
20th Aug 20217:00 amRNSAZD7442 prophylaxis trial met primary endpoint
16th Aug 20213:00 pmRNSDirector/PDMR Shareholding
11th Aug 20212:35 pmRNSUpdate on US review of roxadustat
9th Aug 20217:05 amRNSForxiga approved in the EU for CKD
9th Aug 20217:00 amRNSEnhertu head-to-head trial meets primary endpoint
2nd Aug 20213:00 pmRNSTotal Voting Rights
2nd Aug 20217:00 amRNSSaphnelo approved in the US for SLE
29th Jul 20217:00 amRNSAZN: H1 2021 Results
26th Jul 20217:00 amRNSUltomiris recommended in EU for children with PNH
22nd Jul 20217:00 amRNSDirectorate Change
21st Jul 20213:56 pmRNSDirector/PDMR Shareholding
21st Jul 20213:45 pmRNSTotal Voting Rights
21st Jul 20211:45 pmRNSAcquisition of Alexion completed
19th Jul 20217:00 amRNSImfinzi approved in China for extensive-stage SCLC
16th Jul 20217:00 amRNSStatus on US FDA Advisory Committee for roxadustat
15th Jul 20215:30 pmRNSAstraZeneca
14th Jul 20217:08 amRNSAstraZeneca-Alexion transaction cleared in the UK
8th Jul 20217:00 amRNSTezepelumab granted FDA Priority Review for asthma
6th Jul 20217:00 amRNSAstraZeneca-Alexion transaction cleared in the EU
1st Jul 20213:00 pmRNSTotal Voting Rights
28th Jun 20217:05 amRNSForxiga recommended in EU for patients with CKD
28th Jun 20217:00 amRNSNirsevimab PhII/III trial confirms safety profile
24th Jun 20217:00 amRNSLynparza approved in China for prostate cancer
23rd Jun 20217:00 amRNSOrpathys approved in China for lung cancer
22nd Jun 20217:00 amRNSKoselugo approved in the EU for children with NF1
15th Jun 20217:00 amRNSUpdate on AZD7442 STORM CHASER trial
10th Jun 202111:32 amRNSStabilisation Notice
7th Jun 20217:00 amRNSCalquence head-to-head results versus ibrutinib
4th Jun 20217:05 amRNSLynparza reduced recurrence risk in breast cancer
4th Jun 20217:00 amRNSAstraZeneca appoints new Chief Financial Officer
2nd Jun 20217:00 amRNSPublication of Final Terms
1st Jun 20213:01 pmRNSBlock listing Interim Review
1st Jun 20213:00 pmRNSTotal Voting Rights
28th May 20217:00 amRNSTagrisso approved in EU in early lung cancer
27th May 20214:41 pmRNSSecond Price Monitoring Extn
27th May 20214:36 pmRNSPrice Monitoring Extension
27th May 20217:00 amRNSAstraZeneca prices a EUR800m bond offering
26th May 20219:24 amRNSStabilisation Notice
26th May 20217:00 amRNSAstraZeneca prices a $7bn bond offering
25th May 20217:00 amRNSEMTN programme update - publication of Prospectus

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.